A-
Overall grade
A
Financial quality
The market will focus on the 73% ACR20 response rate, but the real story is that 1402's efficacy paradoxically broke its own Phase II design - when 36% of patients hit ACR70, a randomized withdrawal on ACR20 loss becomes statistically meaningless. This is a 'high quality problem' that suggests Phase III planning is already underway regardless of Period 2 results. The binding constraint isn't efficacy anymore - it's FDA's appetite for approving based on open-label data in a population with zero treatment options. Matt's most revealing moment: 'We're going to be a little bit conservative on what exactly we say from a competitive perspective' about IgG reduction data. My view changes if they don't get FDA alignment on a streamlined registrational path by year-end, turning this efficacy advantage into a development liability.
The 30-second version
- The 1402 RA data quality paradox: ACR70s might torpedo their own Phase II endpoint
- FcRn's commercial validation moment: 85,000 patient market with zero placebo ACR70 interference
- Missing IgG data is the competitive tell they're hiding
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| R&D Expense | $164M Q3 2025 | $175M Q4 2025 |
| Cash Position | $4.5B Q3 2025 | $4.3B Q4 2025 |
| 1402 DTRA Enrollment | 120 patients targeted Q3 | 165 evaluable patients |
| Mosli FOCUS Study | 120 patients targeted Q3 | 135 enrolled |
| ACR20 Response Rate | No prior RA data | 73% at Week 16 |
| ACR70 Response Rate | No comparator available | 36% at Week 16 |
| JAK-Experienced Subset | Not disclosed Q3 | 107 of 165 patients (65%) |
| Moderna Settlement | $2.25B announced Q3 | $950M upfront due July 2026 |
Accountability tracked
8 new promises made3 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →